ARO-MAPT-SC vs Diranersen
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: MAPT mRNA (RNAi/ASO) · full Alzheimer's Disease pipeline
ARO-MAPT-SC
Developed by Arrowhead Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07221344 (registry estimate)
No aligned efficacy figure on record for this race.
Diranersen
Developed by Ionis Pharmaceuticals and partners
NCT03186989 · Phase 1 · completed
This dose-escalation study randomized participants to diranersen or placebo with both participants and staff blinded, but its primary endpoint was safety and tolerability rather than a cognitive or clinical outcome, which limits what it can show about therapeutic effect. Its registered primary outcome on ClinicalTrials.gov is "Part 1: Number of Participants With Adverse Events That Are Related to Treatment With ISIS 814907" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Dose response in Change From Baseline to Week 76 on the CDR-SB: Diranersen/BIIB080 (NCT05399888), Phase 2 CELIA study: primary endpoint (dose-response on CDR-SB change from baseline at Week 76) not met. (missed)
Result source: NCT05399888
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ARO-MAPT-SC | Diranersen |
|---|---|---|
| CDR-SB, change | —Not reported | —Not reported |
| ADAS-Cog11, change | —Not reported | —Not reported |
| ADCS-ADL, change | —Not reported | —Not reported |
| MMSE, change | —Not reported | —Not reported |
| Amyloid PET, change (centiloids) | —Not reported | —Not reported |
CDR-SB, change
- ARO-MAPT-SC
- —Not reported
- Diranersen
- —Not reported
ADAS-Cog11, change
- ARO-MAPT-SC
- —Not reported
- Diranersen
- —Not reported
ADCS-ADL, change
- ARO-MAPT-SC
- —Not reported
- Diranersen
- —Not reported
MMSE, change
- ARO-MAPT-SC
- —Not reported
- Diranersen
- —Not reported
Amyloid PET, change (centiloids)
- ARO-MAPT-SC
- —Not reported
- Diranersen
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ARO-MAPT-SC: no structured comparison results are available for Alzheimer's Disease.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ARO-MAPT-SC: 0 of 4 rows · Diranersen: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Diranersen |
|---|---|
| Dropout rate | 7.7%115 mga NCT03186989 · Phase 1 · monotherapy show 9 more results—115 mg NCT03186989 · Phase 1 · combination —115 mg NCT03186989 · Phase 1 · combination 11.1%60 mg NCT03186989 · Phase 1 · monotherapy —60 mg NCT03186989 · Phase 1 · combination —60 mg NCT03186989 · Phase 1 · combination —60 mg NCT03186989 · Phase 1 · combination —60 mg NCT03186989 · Phase 1 · combination 0%30 mg NCT03186989 · Phase 1 · monotherapy 0%10 mg NCT03186989 · Phase 1 · monotherapy |
| Discontinued due to AEs | —115 mga NCT03186989 · Phase 1 · monotherapy show 9 more results—115 mg NCT03186989 · Phase 1 · combination —115 mg NCT03186989 · Phase 1 · combination —60 mg NCT03186989 · Phase 1 · monotherapy —60 mg NCT03186989 · Phase 1 · combination —60 mg NCT03186989 · Phase 1 · combination —60 mg NCT03186989 · Phase 1 · combination —60 mg NCT03186989 · Phase 1 · combination —30 mg NCT03186989 · Phase 1 · monotherapy —10 mg NCT03186989 · Phase 1 · monotherapy |
| Serious AEs | 0%115 mga NCT03186989 · Phase 1 · monotherapy show 9 more results10%115 mg NCT03186989 · Phase 1 · combination 0%115 mg NCT03186989 · Phase 1 · combination 0%60 mg NCT03186989 · Phase 1 · monotherapy 33.3%60 mg NCT03186989 · Phase 1 · combination 20%60 mg NCT03186989 · Phase 1 · combination 0%60 mg NCT03186989 · Phase 1 · combination 25%60 mg NCT03186989 · Phase 1 · combination 0%30 mg NCT03186989 · Phase 1 · monotherapy 0%10 mg NCT03186989 · Phase 1 · monotherapy |
| Most frequent reported AEs | 115 mga confusional state 23.1% (placebo 0%) post lumbar puncture syndrome 23.1% (placebo 25%) headache 15.4% (placebo 25%) NCT03186989 · Phase 1 · monotherapy show 9 more results115 mg back pain 50% (placebo 8.3%) headache 40% (placebo 25%) fatigue 30% (placebo 0%) NCT03186989 · Phase 1 · combination 115 mg back pain 75% (placebo 8.3%) confusional state 25% (placebo 0%) dementia alzheimer's type 25% (placebo 0%) NCT03186989 · Phase 1 · combination 60 mg headache 33.3% (placebo 25%) procedural pain 33.3% (placebo 8.3%) back pain 22.2% (placebo 8.3%) NCT03186989 · Phase 1 · monotherapy 60 mg agitation 33.3% (placebo 0%) anxiety 33.3% (placebo 0%) back pain 33.3% (placebo 8.3%) NCT03186989 · Phase 1 · combination 60 mg back pain 40% (placebo 8.3%) albumin csf increased 20% (placebo 0%) chronic obstructive pulmonary disease 20% (placebo 0%) NCT03186989 · Phase 1 · combination 60 mg dizziness 42.9% (placebo 8.3%) procedural pain 42.9% (placebo 8.3%) pain in extremity 28.6% (placebo 0%) NCT03186989 · Phase 1 · combination 60 mg pain in extremity 50% (placebo 0%) aggression 25% (placebo 0%) agitation 25% (placebo 0%) NCT03186989 · Phase 1 · combination 30 mg headache 50% (placebo 25%) diarrhoea 33.3% (placebo 0%) nausea 33.3% (placebo 0%) NCT03186989 · Phase 1 · monotherapy 10 mg post lumbar puncture syndrome 50% (placebo 25%) headache 33.3% (placebo 25%) procedural pain 33.3% (placebo 8.3%) NCT03186989 · Phase 1 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ARO-MAPT-SC's landscape · Diranersen's landscape